- Rhone-Poulenc Rorer has received an exclusive license in Canada to market Enzon's Oncaspar (pegaspargase) for the treatment of acute lymphoblastic leukemia in patients who require L-asparaginase therapy but who are hypersensitive to native forms of the enzyme. R-PR already markets Oncaspar in the USA and has scheduled a Canadian launch for 1995.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze